Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines

Full text
Author(s):
Leonel, Camila ; Ferreira, Livia Carvalho ; Borin, Thaiz Ferraz ; Moschetta, Marina Gobbe ; Freitas, Gabriela Scavacini ; Haddad, Michel Raineri ; de Camargos Pinto Robles, Joao Antonio ; Pires de Campos Zuccari, Debora Aparecida
Total Authors: 8
Document type: Journal article
Source: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY; v. 17, n. 8, p. 1113-1125, 2017.
Web of Science Citations: 5
Abstract

Background: ROCK-1 expression is associated with the malignant character of tumors, while inhibiting this molecule results in a significant suppression of tumor metastasis. Likewise, transforming growth factor beta (TGF-beta) is associated with this malignancy by having the ability to induce epithelial-mesenchymal transition (EMT). Metformin, a drug used in the treatment of diabetes, has previously been shown to inhibit EMT in breast cancer cells. Objective: The aim of this study is to evaluate the TGF-beta 1 action model for induction of EMT and the action of metformin and ROCK-1 inhibitor (Y27632) in EMT process in breast cancer cell lines. Method: MCF-7 and MDA-MB-231 cell lines were treated with metformin and Y27632, after induction of EMT by TGF-beta 1, to examine the effects on cell migration as well as the protein expression of the ROCK-1 markers, vimentin, E-cadherin, CD44 and CD24 by immunocitochemistry. Results: There was a lower protein expression of ROCK-1, vimentin, CD44 and CD24 in both cell lines after treatment with metformin and Y27632. In MDA-MB-231 cells, E-cadherin expression was increased in all treatment groups. Treatment of MDA-MB-231 cell line with metformin and Y27632 significantly reduced the invasion of these cells. Conclusion: This study confirms the benefits of metformin and Y27632 as potential therapeutic agents in mammary tumors, by blocking EMT process and metastatic potential. (AU)

FAPESP's process: 12/14079-5 - Metastasis inhibition via epithelial-mesenchymal transition by RNA interference and metformin in mammary neoplasia
Grantee:Debora Aparecida Pires de Campos Zuccari
Support type: Regular Research Grants